Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery
Haifa Shen1, Cristian Rodriguez-Aguayo, Rong Xu
1Department of Nanomedicine, The Methodist Hospital Research Institute, Houston, TX 77030, USA. hshen@tmhs.org
Summary
A novel multistage vector (MSV) system effectively delivers siRNA to ovarian tumors, significantly reducing tumor growth and nodules. This nanotherapeutic shows promise in combination therapies, even against chemotherapy-resistant cancers.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Oncology
Background:
- RNA interference (RNAi) offers targeted gene knockdown for cancer therapy.
- Effective in vivo delivery of small interfering RNA (siRNA) remains a significant challenge.
- A multistage vector (MSV) system using porous silicon particles for nanotherapeutic delivery has been developed.
Purpose of the Study:
- To evaluate the therapeutic efficacy of MSV-loaded EphA2 siRNA (MSV/EphA2) in murine orthotopic models of metastatic ovarian cancer.
- To establish MSV/EphA2 as a potential nanotherapeutic for ovarian cancer treatment.
Main Methods:
- MSV/siRNA tumor accumulation and sustained release were analyzed post-intravenous administration.
- Therapeutic efficacy was assessed in mice with metastatic SKOV3ip2 tumors treated with MSV/EphA2 and paclitaxel.
- Enhanced efficacy was evaluated in docetaxel-resistant HeyA8 ovarian tumors treated with MSV/EphA2 and docetaxel.
Main Results:
- Biweekly MSV/EphA2 treatment (5-15 μg/mice) for 6 weeks yielded dose-dependent reductions in tumor weight (36-83%) and nodule count.
- Combination therapy of MSV/EphA2 and paclitaxel completely inhibited tumor growth in SKOV3ip2 models.
- Combined MSV/EphA2 and docetaxel treatment inhibited growth of docetaxel-resistant HeyA8-MDR tumors.
Conclusions:
- MSV/EphA2 demonstrates significant therapeutic potential in preclinical ovarian cancer models.
- The MSV system facilitates effective siRNA delivery and sustained release in tumor tissues.
- MSV/EphA2 warrants further development as a novel therapeutic agent for ovarian cancer.
